NIAB
National Institute of Animal Biotechnology

राष्ट्रीय पशु जैव प्रौद्योगिकी संस्थान
National Institute of Animal Biotechnology

Seminar Series

13th August 2013

"Antibody Drug Conjugates for Cancer Therapy: Past, Present and Future"

Speaker

Dr. Jagath Reddy Junutula, Ph.D.,

Senior Scientist,

Genentech Inc., San Francisco, CA-USA.

Profile: Dr. Jagath has over 10 years of experience in oncology drug discovery and more than 20 years of experience in the life science research as a biochemist/molecular cell biologist. Supervised and trained researchers in the antibody based discovery projects. Developed a novel THIOMAB technology platform to obtain engineered Antibody Drug Conjugates with defined number of drugs to improve therapeutic utility. Contributed and collaborated with several cross-functional teams in discovery research, pre-clinical research and manufacturing to move antibody based therapeutic molecules from discovery to IND. Authored over 50 patents/peer-reviewed publications and presented work at numerous international conferences.

Abstract: Antibody drug conjugates (ADCs) are attractive targeted chemo-therapeutic molecules as they combine ideal properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to the antigen-expressing tumor cells, thereby enhancing their anti-tumor activity. ADC is a three component molecule and all three components (antibody, linker and cytotoxic drug) are equally important in building a successful ADC therapeutic for a given tumor specific antigen. I will give overview to ADC cancer therapeutics and how various factors influence in developing a successful ADC from bench to clinic.

Venue: Sir C.V. Raman Auditorium, Science Complex, University of Hyderabad

Time: 11:00 AM to 12:00 Noon

All are cordially invited.

Director, NIAB